Condition: End Stage Kidney Disease · Immunological Tolerance · Kidney Transplant Failure and Rejection · Sponsor: University of California, Los Angeles
The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function through hematopoietic stem cell (HPSC) infusion from the same donor. HPSC infusion will be preceded by a conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (rATG).
This description comes directly from the study's public registry record.
Ruth Wynne Jones · 424-402-9564 · rwynnejones@mednet.ucla.edu
Jenny Lester, MPH · 310-794-9728 · jlester@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| UCLA | Los Angeles, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05525507